Group 1 - The Hong Kong Stock Exchange has granted approval for the listing and trading of 183 million H-shares of Fuhong Hanlin on January 19, 2026 [1] - The approval involves converting unlisted shares into H-shares, with participating shareholders holding approximately 33.61% of the company's total shares [1] - Participating shareholders include Shanghai Fosun Pharmaceutical Research Co., Ltd. and Xiamen Health Hongtu Equity Investment Partnership, among a total of 17 shareholders [1] Group 2 - Following the conversion and listing, the company's share structure will change as follows: - Unlisted shares will decrease from 380,066,312 (69.93%) to 197,420,456 (36.32%) - H-shares will increase from 163,428,541 (30.07%) to 346,074,397 (63.68%) [2] - The total number of shares will remain the same at 543,494,853 [2]
复宏汉霖：1.83亿股H股上市及买卖获得香港联交所批准